<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: This Phase IIb, randomized, double-blind, placebo-controlled trial evaluated the efficacy, safety, tolerability and pharmacokinetics of empagliflozin in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Four hundred and eight patients (treatment-naïve or after a 4-week wash-out period) were randomized to receive empagliflozin 5, 10 or 25 mg once daily, placebo or open-label <z:chebi fb="0" ids="6801">metformin</z:chebi> for 12 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>The primary endpoint was change in <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> A1c (HbA1c) after 12 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: After 12 weeks' treatment, empagliflozin showed dose-dependent reductions in HbA1c from baseline [5 mg: -0.4%, 10 mg: -0.5%, 25 mg: -0.6%; <z:hpo ids='HP_0000001'>all</z:hpo> doses p &lt; 0.0001 vs. placebo (+0.09%)] </plain></SENT>
<SENT sid="4" pm="."><plain>Fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) decreased with empagliflozin [5 mg: -1.29 mmol/l, 10 mg: -1.61 mmol/l, 25 mg: -1.72 mmol/l; <z:hpo ids='HP_0000001'>all</z:hpo> doses p &lt; 0.0001 vs. placebo (+0.04 mmol/l)] </plain></SENT>
<SENT sid="5" pm="."><plain>Body weight decreased in <z:hpo ids='HP_0000001'>all</z:hpo> empagliflozin groups (<z:hpo ids='HP_0000001'>all</z:hpo> doses p &lt; 0.001 vs. placebo) </plain></SENT>
<SENT sid="6" pm="."><plain>The incidence of adverse events (AEs) was similar in the placebo (32.9%) and empagliflozin (29.1%) groups </plain></SENT>
<SENT sid="7" pm="."><plain>The most frequently reported AEs on empagliflozin were <z:mp ids='MP_0011535'>pollakiuria</z:mp> (3.3% vs. 0% for placebo), thirst (3.3% vs. 0% for placebo) and <z:e sem="disease" ids="C0027441" disease_type="Disease or Syndrome" abbrv="">nasopharyngitis</z:e> (2.0% vs. 1.2% for placebo) </plain></SENT>
<SENT sid="8" pm="."><plain>AEs consistent with <z:hpo ids='HP_0000010'>urinary tract infections</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">UTIs</z:e>) were reported in four (1.6%) patients on empagliflozin vs. one (1.2%) on placebo </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="C0729552" disease_type="Disease or Syndrome" abbrv="">Genital infections</z:e> were reported in five (2%) patients on empagliflozin vs. 0% on placebo </plain></SENT>
<SENT sid="10" pm="."><plain>No <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">UTIs</z:e> or <z:e sem="disease" ids="C0729552" disease_type="Disease or Syndrome" abbrv="">genital infections</z:e> led to premature discontinuation </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, empagliflozin resulted in dose-dependent, clinically meaningful reductions in HbA1c and FPG, and reductions in body weight compared with placebo </plain></SENT>
<SENT sid="12" pm="."><plain>Empagliflozin was well-tolerated with a favourable safety profile </plain></SENT>
</text></document>